Table II.
Relationship between 21-gene RS and clinicopathological characteristics.
| RS risk groups | |||
|---|---|---|---|
| Clinicopathological characteristics | Low risk (RS <18) | Intermediate/high risk (RS ≥18) | P-value |
| Median age, years (range) | 52 (25–73) | 50 (30–70) | 0.619 |
| Median tumor discovery time, days (range) | 56 (2–1680) | 28 (2–1680) | 0.317 |
| Occupation | 0.507 | ||
| Manual worker | 15 (26.8) | 13 (38.2) | |
| Skilled worker | 22 (39.3) | 12 (35.3) | |
| Unemployed | 19 (33.9) | 9 (26.5) | |
| BMI | 0.008 | ||
| <24 | 49 (75.4) | 23 (51.1) | |
| ≥24 | 16 (24.6) | 22 (48.9) | |
| Menopausal state | 0.902 | ||
| Postmenopausal | 34 (52.3) | 23 (51.1) | |
| Premenopausal | 31 (47.7) | 22 (48.9) | |
| Tumor size | 0.113 | ||
| ≤2 | 47 (72.3) | 26 (57.8) | |
| >2 | 18 (27.7) | 19 (42.2) | |
| Pathological type | 0.001 | ||
| IDC | 49 (75.4) | 44 (97.8) | |
| NIDC | 16 (24.6) | 1 (2.2) | |
| Histological grade | 0.010 | ||
| I–II | 51 (82.3) | 25 (59.5) | |
| III | 11 (17.7) | 17 (40.5) | |
| Clinical stage | 0.113 | ||
| Stage I | 47 (72.3) | 26 (57.8) | |
| Stage II–III | 18 (27.7) | 19 (42.2) | |
| Molecular type | 0.022 | ||
| Luminal A | 33 (50.8) | 13 (28.9) | |
| Luminal B | 32 (49.2) | 32 (71.1) | |
| Surgical scheme | 0.764 | ||
| BCS | 10 (15.4) | 6 (13.3) | |
| BMS | 55 (84.6) | 39 (86.7) | |
| Median P53% (range) | 8 (1–90) | 10 (1–90) | 0.099 |
| CK5/6 status | |||
| Positive | 4 (6.8) | 5 (11.1) | 0.670 |
| Negative | 55 (93.2) | 40 (88.9) | |
| Median CEA, ng/ml (range) | 1.50 (0.31–4.62) | 1.52 (0.20–5.73) | 0.771 |
| Median CA15-3, ng/ml (range) | 9.37 (4.67–25.48) | 11.12 (4.85–28.48) | 0.215 |
Bold indicates P<0.05. BCS, breast conserving surgery; BMI, body mass index; BMS, breast mastectomy surgery; CA15-3, cancer antigen 15-3; CEA, carcinoembryonic antigen; CK5/6, cytokeratin 5/6; IDC, invasive ductal carcinoma; NIDC, non-invasive ductal carcinoma; RS, recurrence score.